Crescent Biopharma, Inc.
$21.69
▲
0.41%
2026-04-21 05:54:01
crescentbiopharma.com
NCM: CBIO
Explore Crescent Biopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$575.8 M
Current Price
$21.69
52W High / Low
$29 / $8.72
Stock P/E
—
Book Value
$5.99
Dividend Yield
—
ROCE
-74.74%
ROE
-1.61%
Face Value
—
EPS
$-12.81
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
44
Beta
—
Debt / Equity
0.81
Current Ratio
6.56
Quick Ratio
6.56
Forward P/E
-5.08
Price / Sales
51.02
Enterprise Value
$395.95 M
EV / EBITDA
-2.6
EV / Revenue
36.51
Rating
Strong Buy
Target Price
$29.29
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Caris Life Sciences, Inc. | $21.24 | — | $5.98 B | — | 4.52% | -45.37% | $42.5 / $16.28 | $2.04 |
| 2. | Vivani Medical, Inc. | $1.51 | — | $127.82 M | — | -84.04% | -1.6% | $1.92 / $0.92 | $0.21 |
| 3. | Rocket Pharmaceuticals, Inc. | $3.86 | — | $421.21 M | — | -76.11% | -60.27% | $8.26 / $2.19 | $2.56 |
| 4. | Harmony Biosciences Holdings, Inc. | $29.53 | 10.93 | $1.73 B | — | 20.45% | 20.75% | $40.87 / $25.52 | $15.07 |
| 5. | Kairos Pharma, Ltd. | $0.63 | — | $13.1 M | — | -87.87% | -97.99% | $2.11 / $0.4 | $0.37 |
| 6. | CervoMed Inc. | $3.97 | — | $36.76 M | — | -155.27% | -93.92% | $13.13 / $3.51 | $1.97 |
| 7. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q4 2024 | |
|---|---|---|---|---|
| Sales | 10.84 M | 0 M | 0 M | 0 M |
| Operating Profit | -91.49 M | -25.89 M | -21.03 M | -17.19 M |
| Net Profit | -92.4 M | -24.61 M | -21.79 M | -17.87 M |
| EPS in Rs | -3.35 | -0.89 | -0.79 | -0.65 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | |
|---|---|---|
| Sales | 10.84 M | — |
| Operating Profit | -152.63 M | — |
| Net Profit | -153.94 M | — |
| EPS in Rs | -5.59 | — |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | |
|---|---|---|
| Total Assets | 240.29 M | 35.62 M |
| Total Liabilities | 37.28 M | 51.1 M |
| Equity | 203.01 M | -15.48 M |
| Current Assets | 236.66 M | 34.8 M |
| Current Liabilities | 36.07 M | 9.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | |
|---|---|
| Operating CF | -71.53 M |
| Investing CF | -72.92 M |
| Financing CF | 322.98 M |
| Free CF | -144.45 M |
| Capex | -72.92 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | |
|---|---|
| Revenue Growth % | — |
| Earnings Growth % | — |
| Profit Margin % | -1419.61% |
| Operating Margin % | -1407.52% |
| Gross Margin % | — |
| EBITDA Margin % | -1380.24% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2023-01-13 | $24 |
| 2022-09-21 | $143 |
Stock Splits
| Date | Split |
|---|---|
| 2025-06-16 | 1:0.01 |